1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > In-depth Research on China Animal Vaccine Industry, 2014

In-depth Research on China Animal Vaccine Industry, 2014

  • February 2014
  • -
  • Huidian Research
  • -
  • 101 pages

At present, there are 88 animal vaccine manufacturers in China, with 338 production lines. But most of enterprises are small in scale, vaccine production inspection is not standard and product structures are not reasonable. Market shares are occupied by a minority of enterprises.

According to the statistics by China Veterinary Drug Association (CVDA), the production capacity of live vaccines was 344.58 billion doses in 2012; the production capacity of inactivated vaccines was 55.392 billion milliliters; in China's animal vaccine industry, the annual sales revenue reached CNY 8.888 billion in 2012, and the top 10 enterprises as for sales revenue accounted for 50% of total sales revenue of biological products.

Among the key animal vaccine manufacturers in China in 2012, China Animal Husbandry Industry Co., Ltd (CAHIC) obtained the most business income registering CNY 1.17 billion, accounting for 13.16% market share. TECON, Dahuanong, Jinyu Group and Ringpu also had more than 5% market share respectively.

According to the survey by Huidian Research, the growth of China's animal vaccine market was slowing down in 2013, it was estimated that year-on-year growth was about 15% and the market scale reached CNY 10.22 billion in 2013, of which, swine vaccine accounted for 50% shares and poultry vaccine accounted for 36%.

Table Of Contents

In-depth Research on China Animal Vaccine Industry, 2014
1. Development Environment of China's Animal Vaccine Industry
1.1 Market Characteristics
1.1.1 Industry Definition
1.1.2 Industry Characteristics
1.2 Economic Environment
1.3 Policy Environment
1.3.1 Industry Related Policy
1.3.2 Influence of Related Policy

2. Technology Development of China's Animal Vaccine Industry
2.1 Product Technology Maturity
2.2 Technology Gap between China and Foreign Countries and Main Reasons
2.3 Strategy for Improving China's Technology

3. Development of China's Animal Vaccine Industry
3.1 Swine Vaccine
3.2 Poultry Vaccines
3.3 Pet Vaccines

4. Economic Operation of Animal Vaccine Industry
4.1 Industry Production and Sales in 2012
4.2 Industry Scale, 2008-2013
4.3 Industry Profit in 2012
4.4 Industry Profitability in 2012
4.5 Industry Business Development Capacity in 2012
4.6 Industry Debt Paying Ability in 2012

5. Import and Export of China's Animal Vaccine
5.1 Import
5.2 Export

6. Effect of Industry Competition Landscape on Investment in China, 2013
6.1 Porter Five Forces Analysis of China's Animal Vaccine Industry
6.1.1 Competition between the Existing Enterprises
6.1.2 Potential New Entrant
6.1.3 Substitute
6.1.4 Bargaining Power of Supplier
6.1.5 Bargaining Power of Customers
6.2 Competition Landscape of China's Animal Vaccine Industry
6.3 Competition Forecast of China's Animal Vaccine Industry

7. Domestic Key Enterprises, 2013
7.1 China Animal Husbandry Industry Co., Ltd. (CAHIC)
7.1.1 Company Profile
7.1.2 Business Performance
7.1.3 Company Competitiveness
7.1.4 Development Strategy
7.2 Qingdao Yebio Bioengineering Co., Ltd.
7.2.1 Company Profile
7.2.2 Business Performance
7.2.3 Company Competitiveness
7.3 Guangdong Dahuanong Animal Health Products Co. Ltd.
7.3.1 Company Profile
7.3.2 Business Performance
7.3.3 Company Competitiveness
7.3.4 Development Strategy
7.4 TECON
7.4.1 Company Profile
7.4.2 Business Performance
7.4.3 Company Competitiveness
7.4.4 Development Strategy
7.5 Inner Mongolia Jinyu Group Stock Company
7.5.1 Company Profile
7.5.2 Business Performance
7.5.3 Company Competitiveness
7.5.4 Development Strategy
7.6 Tianjin Ringpu Bio-technology Co., Ltd.
7.6.1 Company Profile
7.6.2 Business Performance
7.6.3 Marketing Channel
7.7 Chengdu TECBOND Biological Products Co., Ltd.
7.7.1 Company Profile
7.7.2 Business Performance
7.7.3 Competitiveness
7.7.4 Development Strategy

8. Investment Analysis of Animal Vaccine Industry, 2014-2018
8.1 Investment Opportunity
8.2 Investment Risk
8.2.1 Policy Risk
8.2.2 Market Risk
8.2.3 Application Risk
8.2.4 Technology Risk
8.3 Industry Barriers to Entry
8.3.1 Administrative Barriers to Entry
8.3.2 Technical Barrier
8.3.3 Brand Barrier
8.3.4 Management Barrier
8.3.5 Capital Barrier
8.4 Industry Investment Proposals

9. Investment Opportunity and Risk of Animal Vaccine Industry
9.1 Investment Opportunity of China's Animal Vaccine Industry
9.1.1 Investment Opportunity
9.1.2 Feasibility Study
9.2 Investment Efficiency of Animal Vaccine Industry
9.2.1 Investment Status
9.2.2 Investment Efficiency
9.2.3 Investment Trend Forecast
9.2.4 Investment Orientation


Companies Mentioned

China Animal Husbandry Industry Co., Ltd. (CAHIC)
Qingdao Yebio Bioengineering Co., Ltd.
Guangdong Dahuanong Animal Health Products Co. Ltd.
TECON
Inner Mongolia Jinyu Group Stock Company
Tianjin Ringpu Bio-technology Co., Ltd.
Chengdu TECBOND Biological Products Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.